NCT04926701View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

ETD001 single dose

Single ascending doses of inhaled ETD001

DRUG

Placebo single dose

Single doses of inhaled placebo

DRUG

ETD001 multiple twice daily doses

Ascending doses of inhaled ETD001 administered twice daily

DRUG

Placebo multiple twice daily doses

Doses of inhaled placebo administered twice daily

DRUG

ETD001 multiple once daily doses

Doses of inhaled ETD001 administered once daily

DRUG

Placebo multiple once daily doses

Doses of inhaled placebo administered once daily

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
lead

Enterprise Therapeutics Ltd

INDUSTRY

NCT04926701 - A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects | Biotech Hunter | Biotech Hunter